Bojan Kopilovic

Bojan Kopilovic

Auto-generated profile, based on publicly available information

Bojan Kopilovic

School of Chemical, Materials and Biological Engineering

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2023 in RSC Sustainability
Verified
Journal Article
Open access
PDF file
BKBojan Kopilovic
Bojan Kopilovic
AVAna Isabel Bastos Valente
Ana Isabel Bastos Valente
Ana FerreiraAna Ferreira
Ana Ferreira
MAMafalda R. Almeida
Mafalda R. Almeida
ATAna P. M. Tavares
Ana P. M. Tavares
JCJoao Coutinho
Joao Coutinho
Advances towards the development of a sustainable economy must address the exploitation of bio-based products combined with the use of greener solvents and manufacturing processes that can preserve natural resources and the environment. To address the growing demand for proteins, their production must focus on non-animal sources, such as vegetal biomass and respective residues/waste, and on the use of sustainable solvents and processes for their recovery. This review provides an overview of the advances achieved in the separation and purification processes of proteins from vegetable biomass and respective residues using ionic liquids (ILs) and deep eutectic solvents (DESs) as alternative greener solvents. It begins with an overview of the ability of ILs and DESs to stabilize proteins, followed by the assessment of the extraction and separation of biomass-derived proteins assisted by ILs and DESs. Different types of non-animal biomass and respective residues are considered as protein resources, i.e., algae, plants (e.g., aloe vera and holy basil), cereals (e.g., wheat and oat), fruits (e.g., papaya, pineapple, pomegranate, and seabuckthorn berries), and vegetables (e.g., spinach, radish, and ginger). Several IL- and DES-based approaches are discussed, comprising (i) conventional solid–liquid extraction (SLE), (ii) ultrasound-assisted extraction (UAE), (iii) microwave-assisted extraction (MAE), and (iv) aqueous biphasic systems (ABSs). Finally, the economic and environmental challenges of using such alternative solvents in industrial applications are discussed, including technoeconomic analysis and life cycle assessment.

30 October 2025 in Molecular Pharmaceutics
Verified
Journal Article
Open access
CDCallum George Davidson
Callum George Davidson
EKEleni Kapsali
Eleni Kapsali
SISavvas Ioannou
Savvas Ioannou
BKBojan Kopilovic
Bojan Kopilovic
MHMuattaz Hussain
Muattaz Hussain
Zahra RattrayZahra Rattray
Zahra Rattray
The number of nucleic acid therapeutics is set to grow within the pharmaceutical industry sector, deploying nanocarrier-based delivery systems as drug products. Poly(A) is a widely used model sequence used in lipid nanoparticle (LNP) formulations for which there are no reported critical quality attributes (CQAs) such as molecular weight, chain length, and impurity profile. In this study, we analyze Poly(A) from three different vendors to measure any existing differences in their CQAs. Poly(A) from these brands was encapsulated in SM102 LNPs using microfluidics to produce three branded Poly(A)-based LNPs. We utilized an orthogonal analytical pipeline approach for both Poly(A) drug substance and LNP drug product CQA evaluation, which included a combination of dynamic light scattering and flow field flow fractionation multiplexed with inline UV, dynamic, and multiangle light-scattering detectors. Similar purity (260/280) values of >3 were obtained across all three brands of Poly(A); however, distinct differences in molecular weight and chain length distributions were identified across Poly(A) brands, with this study representing the first to apply EAF4 methodology for in-depth characterization of model RNA drug substances. Brand A produced a smaller and broader molecular weight distribution, followed by Brand B, and then Brand C produced the largest molecular weight species and the most uniform molecular weight distribution. On encapsulation in LNPs, differences seen in Poly(A) CQAs did not translate to CQA differences in resultant LNPs. We show that a deeper understanding of drug substance CQAs and their subsequent impact on resultant overall drug product characteristics is needed on a case-by-case basis. We show correlations between analytical pipelines, with future work investigating the impact of RNA molecular weight in LNP formulations with different lipid compositions and using these correlations in AI or machine learning to further enhance our knowledge of the correlation between drug substance and resultant drug product CQAs.

13 June 2025 in Materials Today Bio
Verified
Journal Article
Open access
BKBojan Kopilovic
Bojan Kopilovic
NLNabila LAROUI
Nabila LAROUI
MBMathieu Berchel
Mathieu Berchel
PJPaul-Alain Jaffrès
Paul-Alain Jaffrès
PMPatrick Midoux
Patrick Midoux
Chantal PichonChantal Pichon
Chantal Pichon
Efficient delivery of messenger ribonucleic acid (mRNA) to mucosal tissues represents a promising approach for localized protein production in the nasal and respiratory tract. Here, we investigate the use of maltodextrin (MDX) as a surface modifier to enhance the delivery of mRNA-loaded histidylated lipoplexes (LXs) to airway epithelial cells. By reducing hydrophobicity, MDX facilitates better penetration through the mucus layer, enabling effective mRNA delivery. MDX-coated LXs improve mRNA delivery and expression in vitro by increasing cellular uptake and supporting sustained protein production. Additionally, MDX incorporation stabilizes in-house-formulated lipoplexes and modulates their interactions with mucin-covered cells. Notably, MDX-coated mRNA LXs display a four-fold increased transfection efficiency, and the protein expression is maintained up to 48 h post-transfection. Furthermore, intranasal administration of MDX-LXs results in efficient gene expression in vivo. Overall, our findings reveal that integrating MDX into mRNA lipoplexes is a promising strategy to advance nasal delivery for gene therapy and protein replacement applications.

1 November 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
BKBojan Kopilovic
Bojan Kopilovic
JSJoas Sterk
Joas Sterk
TMThomas C Minshull
Thomas C Minshull
CMCriag Murdoch
Criag Murdoch
MDMark J Dickman
Mark J Dickman
ZKZoltán Kis
Zoltán Kis